1. Home
  2. PTC vs ILMN Comparison

PTC vs ILMN Comparison

Compare PTC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Inc.

PTC

PTC Inc.

HOLD

Current Price

$137.06

Market Cap

17.8B

Sector

Technology

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$131.44

Market Cap

19.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTC
ILMN
Founded
1985
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8B
19.4B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
PTC
ILMN
Price
$137.06
$131.44
Analyst Decision
Buy
Hold
Analyst Count
12
17
Target Price
$182.83
$124.24
AVG Volume (30 Days)
1.0M
1.2M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
94.87
170.87
EPS
1.39
5.45
Revenue
$2,739,226,000.00
$4,343,000,000.00
Revenue This Year
$0.43
$6.52
Revenue Next Year
$6.22
$5.60
P/E Ratio
$98.28
$24.26
Revenue Growth
19.18
N/A
52 Week Low
$130.89
$69.88
52 Week High
$219.69
$155.53

Technical Indicators

Market Signals
Indicator
PTC
ILMN
Relative Strength Index (RSI) 36.80 58.34
Support Level N/A $127.99
Resistance Level $148.00 $136.86
Average True Range (ATR) 4.48 4.99
MACD -0.20 0.94
Stochastic Oscillator 36.70 89.24

Price Performance

Historical Comparison
PTC
ILMN

About PTC PTC Inc.

PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: